Repligen

Repligen

Life Sciences Tools & Services
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

$11.1B

Market Cap • 11/6/2026

1981

(45 years)

Founded

1986

(40 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

5,3

P/S

13,8

P/EBITDA

115,4

P/OCF

85,4

P/FCF

103,9

P/E

—

BVPS

32,7

EPS

—

Market Cap

Market Cap

11,1B

EV

10,9B

EV/Revenue

13,6

EV/EBITDA

113,6

EV/EBIT

598,7

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,1%

Total Yield

-0,1%

Payout

0%

Retained Earnings

431,2M

Profitability

Gross Margin

53,5%

EBITDA Margin

11,9%

EBIT Margin

2,3%

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

7,1%

Capex/Revenue

2,9%

Capex/D&A

29,7%

Capex/OCF

17,8%

SBC/OCF

25,9%

% PPE

9,4%

% Goodwill

37,6%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

6,3%

CAGR Op. Income 5Y

-34,1%

CAGR OCF 5Y

9%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

9,9

Quick Ratio

8,1

Interest Coverage

97,9%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium